NCT05730907

Efficacy and Clinical Outcomes of Levosimendan in E-CPR

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 100 (estimated)
• Sponsor: Hamad Medical Corporation · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: —

Summary

Treatment of refractory cardiac arrest requiring cardiopulmonary resuscitation (CPR) may be augmented with Extracorporeal membrane oxygenation (ECMO) to re-establish perfusion in the absence of return of spontaneous circulation. Literature has demonstrated that ECMO initiated during advanced cardiopulmonary life support may confer superior survival rates with acceptable survival and a relatively low incidence of significant neurologic impairment. Levosimendan has not been investigated in patients with cardiac arrest who underwent Extracorporeal CPR (E-CPR). The current study aims to examine whether levosimendan use in the aforementioned patient population could improve survival and ECMO parameters.

Conditions

• Cardiogenic Shock
• Extracorporeal Membrane Oxygenation Complication

Interventions

Type	Name	Description
DRUG	Levosimendan	examine whether levosimendan could improve in-hospital survival with good neurological outcomes in patients with cardiac arrest supported by E-CPR

Timeline

• Start date: 2023-02-20
• Primary completion: 2023-04-30
• Completion: 2023-04-30
• First posted: 2023-02-16
• Last updated: 2023-02-16

Locations

1 site across 1 country: Qatar